Bullish
This article details Cencora's Specialty Distribution Services, highlighting its crucial role in the logistics of complex pharmaceuticals, particularl...
Cencora, Inc. (NYSE: COR) announced it will release its Third Quarter Fiscal 2026 results on Wednesday, August 5, 2026, before the New York Stock Exch...
Cencora, Inc.'s Chief Financial Officer, Eva C. Boratto, was granted 21,304 Restricted Stock Units (RSUs) for no cash consideration. These RSUs will v...
Cencora's Chief Financial Officer, Eva C. Boratto, filed an initial Form 3, reporting a small ownership position in the company's common stock. The fi...
Bearish
Cencora Inc. (COR) stock fell by 1.57% to $281.65 on Monday, underperforming the broader market. This downturn occurred despite a positive trading ses...
Neutral
Jared Moskowitz, the representative for Florida’s 23rd congressional district, recently carried out stock transactions involving Cencora, Inc. and Gil...
Bullish
Pharmagen, a Cencora Inc. brand, specializes in providing injectable generics and compounded therapies for hospitals and health systems, particularly ...
Neutral
BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 46.8% during the 1st quarter, Hol...
Bullish
Cencora has launched "Cencora Connect Pro," a new cloud-based platform designed to streamline specialty drug ordering, inventory management, and reimb...
Neutral
Cencora has announced Samantha Hammock as its new Executive Vice President and Chief Human Resources Officer, effective July 13, 2026. She succeeds Si...
Bullish
Cencora Inc. shares have seen a steady climb, drawing investor attention to the company's valuation in relation to its fundamentals and the US market....
Bullish
Cencora's role in the U.S. healthcare market is being shaped by specialty drug demand, healthcare distribution, working capital discipline, margin con...
/Cencora%20Inc_%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Neutral
Cencora, Inc. (COR) is underperforming the Nasdaq Composite, with its stock declining significantly over the past three months and year-to-date. This ...
Pomerantz LLP is investigating potential claims on behalf of investors of Cencora, Inc. (NYSE: COR) following a significant drop in its stock price. T...